Lung Cancer
Latest News
ACS expands lung cancer screening eligibility
Greater uptake and adherence needed to reduce deaths.
Commentary
How to think about second-line therapy in NSCLC
We really have to do better.
Conference Coverage
Neoadjuvant, adjuvant, or both? The debate in NSCLC rages on
The question of whether to give upfront immunochemotherapy in resectable non–small cell lung cancer, wait until after surgery, or give both...
Conference Coverage
‘We finally made it’: Amivantamab comes of age in NSCLC
Data from three trials with amivantamab in advanced EGFR-mutant NSCLC have yielded “exciting” results with experts hailing the drug as standard of...
Conference Coverage
ALK inhibitor alectinib shows DFS benefit in early NSCLC
Interim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs. chemotherapy in resected stage IB-IIIA NSCLC....
Conference Coverage
Perioperative nivolumab improves EFS in resectable NSCLC
Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs. neoadjuvant nivolumab plus...
Commentary
Neoadjuvant advantages: Treating locally advanced lung cancer
I think that it’s time to change some of our standards. When patients appear with lung cancers other than tiny ones that might be detected through...
From the Journals
This is how you get patients back for follow-up cancer testing
“What concerns me is that despite the various interventions implemented to encourage and support patients to return for follow-up testing, over 60...
Conference Coverage
Higher RT doses can boost lifespan, reduce risk of death in LS-SCLC patients
“We need more technical details to understand how to deliver this regimen in clinical practice, and it may not be applicable for all patients.”
Conference Coverage
Reducing cognitive impairment from SCLC brain metastases
Stereotactic radiosurgery was better at preventing loss of verbal recall function at 3 months than whole-brain radiation therapy, the current...
Latest News
These adverse events linked to improved cancer prognosis
Emerging evidence suggests that cutaneous immune-related adverse events may be linked with favorable outcomes among patients with cancer who...